Table 2.
Angiographic and procedural characteristics
| Variable, n (%) | Placebo (n=11) | Drug (n=11) | p Value* |
|---|---|---|---|
| Number of diseased vessels (>70% stenosis) | 1=4 (36) | 1=5 (45.5) | 0.80 |
| 2=5 (46) | 2=5 (45.5) | ||
| 3=2 (18) | 3=1 (9) | ||
| Culprit vessel | LAD=3 (27) | LAD=6 (55) | 0.43 |
| LCx=3 (27) | LCx=2 (18) | ||
| RCA=5 (46) | RCA=3 (27) | ||
| Vessels treated | 1=8 (73) | 1=10 (91) | 0.27 |
| 2=3 (27) | 2=1 (9) | ||
| GP IIb/IIIa inhibitor use | 7 (64) | 7 (64) | 1.00 |
| Clopidogrel before PCI | 1 (9) | 2 (18) | 0.53 |
| Clopidogrel during PCI | 10 (91) | 9 (82) | 0.53 |
| Days from symptom onset to PCI† | 0.61 | ||
| 1 | 3 (27) | 3 (30) | |
| 2 | 2 (18) | 2 (20) | |
| 3 | 1 (9) | 2 (20) | |
| 4 | 1 (9) | 1 (10) | |
| 5 or more | 4 (36) | 2 (20) | |
| ACC/AHA lesion severity grade | A=1 (9.1), B=9 (81.8), C=1 (9.1) | A=1 (9.1), B=7 (63.6), C=1 (27.3) | 0.54 |
| Culprit lesion stenosis, % | 88±8 | 85±9 | 0.56 |
| Stent type | BMS=4 (36) | BMS=0 | 0.027 |
| DES=7 (64) | DES=11 (100) | ||
| Maximum stent diameter, mm | 3.5 (2.5, 4) | 2.75 (2.5, 3) | 0.051 |
| Total stent length, mm | 13 (13, 18) | 13 (13, 18) | 0.73 |
| Max stent deployment pressure, mm Hg | 15±2.5 | 14±2.3 | 0.19 |
| Baseline LVEF, % | 57±7.4 | 60±7 | 0.43 |
Data are expressed as number (percentage), median (IQR) and mean±SD.
*p Values for pretreatment comparisons are provided for descriptive purposes.
†Days from symptom onset to PCI were unknown for one participant in the drug group.
ACC/AHA, American College of Cardiology/American Heart Association; BMS, bare metal stent; DES, drug-eluting stent; GP, glycoprotein; LAD, left anterior descending artery; LCx, left circumflex artery; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; RCA, right coronary artery.